Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostics Molecular Tests


ThyGenX ThyraMIR logos

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient


PancraGen logo

PancraGEN™ is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient.

I am a physician
I am a patient

In the Pipeline: Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Barrett’s Esophagus

Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

BarreGEN Logo

Pancreatobiliary Cancer

Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings


Galaxy Health Network To Cover All Products

PARSIPANNY, N.J., April 5, 2016 /PRNewswire/ — Interpace Diagnostics Corp. (NASDAQ: IDXG) a company providing high value molecular diagnostics tests and pathology services announced today that it has signed an agreement with Galaxy Health Network to provide coverage for all of Interpace’s molecular pathology tests and services.  This agreement includes ThyGenX®/ThyraMIR™, a combination test that can improve the pre-operative diagnosis and surgical management of patients with indeterminate thyroid nodules, and PancraGEN™ for the diagnosis and risk stratification of pancreatic cancer from suspicious cysts. […]

Interpace Diagnostics Implements Measures Resulting in Significant 2016 Savings

PARSIPPANY, N.J., March 23, 2016 /PRNewswire/ — Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“IDX”) today reported the implementation of a broad-based program to maximize efficiencies and cut costs designed to improve cash flows and profitability while completing the transition to a standalone high-value molecular diagnostics business. […]

America’s Choice Provider Network to Cover Tests for Thyroid and Pancreatic Cancer

Interpace Diagnostics Announces Agreement with America’s Choice Provider Network to Cover All of the Company’s Molecular Tests for Thyroid and Pancreatic Cancer […]

View All


  • DrLorenVideoThumb

Managing Patients With Pancreatic Cystic Lesions

David Loren, MD, Thomas Jefferson University, shares data on the molecular test, PancraGen, which helps identify false negative cases that could be missed by first-line tests like imaging, cytology and fluid chemistry. […]